证券代码：002370 证券简称：亚太药业 公告编号：2024-037 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于不向下修正"亚药转债"转股价格的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、截至 2024 年 4 月 26 日，浙江亚太药业股份有限公司（以下 简称"亚太药业"或"公司"）股票已出现任意连续三十个交易日中 至少有十五个交易日的收盘价低于当期转股价格的 85%的情形，触发 "亚药转债"转股价格向下修正条款。 2、经公司第七届董事会第二十五次会议审议通过，公司董事会 决定本次不向下修正"亚药转债"转股价格。从 2024 年 4 月 29 日开 始重新起算，若再次触发"亚药转债"的转股价格向下修正条款，届 时公司董事会将再次召开会议决定是否行使"亚药转债"转股价格 的向下修正权利。敬请广大投资者注意投资风险。 一、可转换公司债券基本情况 经深圳证券交易所"深证上〔2019〕224号"文同意，公司9.65亿 元可转换公司债券已于2019年4月24日在深圳证券交易所上市交易， 债券简称"亚药转债"，债 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-033 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、董事会会议通知的时间和方式 浙江亚太药业股份有限公司（以下简称"公司"）第七届董事会 第二十五次会议（以下简称"会议"）通知于 2024 年 4 月 19 日以专 人送达、微信等方式送达各位董事。 2、召开董事会会议的时间、地点和方式 会议于 2024 年 4 月 26 日以通讯表决方式召开。 3、董事会会议出席情况 本次会议的应表决董事 9 人，实际参与表决董事 9 人，其中独立 董事 3 人。 4、本次会议的通知、召开以及参与表决董事人数均符合相关法 律、法规、规则及《公司章程》的有关规定。 二、董事会会议审议情况 关于第七届董事会第二十五次会议决议的公告 1 （二）以 9 票同意，0 票反对，0 票弃权，审议通过了《关于变 更部分募集资金专用账户的议案》 具体内容详见 2024 年 4 月 27 日公司在指定信息披露媒体《证券 时报》和巨潮 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥112,712,517.95, a decrease of 8.80% compared to ¥123,584,310.47 in the same period last year[4] - The net loss attributable to shareholders was ¥2,998,386.71, representing a 14.49% increase in loss from ¥2,618,854.09 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 112,712,517.95, a decrease of 8.5% compared to CNY 123,584,310.47 in the same period last year[19] - Net profit for Q1 2024 was a loss of CNY 2,998,386.71, compared to a loss of CNY 2,618,854.09 in Q1 2023, reflecting a deterioration in performance[20] Cash Flow - The net cash flow from operating activities improved significantly to ¥7,687,843.33, a 408.27% increase from -¥2,493,862.07 in the previous year[4] - Operating cash flow for Q1 2024 was CNY 7,687,843.33, a significant improvement from a negative cash flow of CNY 2,493,862.07 in the same quarter last year[22] - The net cash flow from investing activities was -¥2,890,338.00, a 154.22% increase in cash outflow compared to -¥1,136,941.50 in the previous year[10] - The net cash flow from financing activities was -¥61,901,761.80, a significant increase in cash outflow of 313.20% from -¥14,981,172.78 year-on-year[10] - Cash inflow from financing activities totaled 50,000,000.00, while cash outflow was 61,901,761.80, resulting in a net cash flow of -61,901,761.80, compared to -14,981,172.78 previously[23] - The net increase in cash and cash equivalents was -57,104,256.47, down from -18,611,976.35 in the prior period, reflecting a decline in liquidity[23] - The ending balance of cash and cash equivalents was 663,138,268.39, compared to 703,824,887.55 at the end of the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,362,635,349.17, down 4.67% from ¥1,429,373,407.82 at the end of the previous year[4] - Total current assets decreased from 955,179,993.71 to 897,221,234.63, a decline of approximately 6.1%[16] - Total liabilities decreased to CNY 784,725,256.60 from CNY 848,498,998.29, indicating improved financial health[20] - Total current liabilities decreased from 161,802,829.27 to 101,490,071.11, a decline of approximately 37.3%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 64,587[12] - The largest shareholder, Ningbo Fubang Holdings, holds 14.68% of shares, totaling 89,420,000 shares[12] Expenses - Total operating costs for Q1 2024 were CNY 114,454,069.55, down 9.4% from CNY 126,382,479.22 year-over-year[19] - Sales expenses decreased to CNY 14,316,311.00 in Q1 2024 from CNY 19,599,947.10 in Q1 2023, a reduction of 26.9%[19] - Financial expenses decreased by 49.00% to ¥5,203,577.16, primarily due to reduced interest expenses on convertible bonds[8] - Financial expenses decreased significantly to CNY 5,203,577.16 from CNY 10,203,797.54, a reduction of 48.9% year-over-year[19] Research and Development - The company has ongoing research and development efforts, with development expenditures increasing from 11,133,234.46 to 12,557,762.76[16] - Research and development expenses for Q1 2024 were CNY 4,643,430.60, slightly up from CNY 4,608,303.89 in Q1 2023, indicating continued investment in innovation[19] Other Information - The company received government subsidies amounting to ¥346,429.75 during the reporting period[6] - The company has not reported any significant changes in shareholder relationships or actions related to share lending[13] - The company did not conduct an audit for the first quarter report, indicating that the figures are unaudited[24] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[24]

证券代码：002370 证券简称：亚太药业 公告编号：2024-032 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会未出现否决议案的情形； 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2024 年 4 月 19 日下午 14：00 网络投票时间： 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 4 月 19 日上午 9:15—9:25，9:30－11:30，下午 13:00－15:00； 通过深圳证券交易所互联网投票系统 （http://wltp.cninfo.com.cn）投票的具体时间为 2024 年 4 月 19 日上午 9：15 至下午 15：00 的任意时间。 2、现场会议召开地点：浙江省绍兴滨海新城沥海镇南滨西路 36 号办公楼三楼会议室 3、会议召集人：浙江亚太药业股份有限公司董事会。 4、会议召开方式：本次会议采取现场投票和网络投票相结合的 2、本次股东大 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-031 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于亚药转债预计触发转股价格向下修正条件的提 示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 | 股票代码：002370 | 股票简称：亚太药业 | | --- | --- | | 债券代码：128062 | 债券简称：亚药转债 | | 当前转股价格：4.21 元/股 | | 转股日期：2019 年 10 月 9 日至 2025 年 4 月 2 日 本次触发转股价格修正条件的期间从 2024 年 4 月 8 日起算，截 至 2024 年 4 月 19 日，公司股票已有 10 个交易日的收盘价格低于当 期转股价格的 85%，预计触发转股价格向下修正条件。敬请广大投资 者注意投资风险。 一、可转换公司债券基本情况 经中国证券监督管理委员会《关于核准浙江亚太药业股份有限公 司公开发行可转换公司债券的批复》（证监许可〔2019〕225号）核 准，公司于2019年4月2日公开发行了965万张可转换公司债券，每张 ...

北京国枫（杭州）律师事务所 关于浙江亚太药业股份有限公司 2023 年度股东大会的 法律意见书 国枫律股字[2024]G0003 号 致：浙江亚太药业股份有限公司（贵公司） 北京国枫（杭州）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2023 年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《上市公司股东大会规则》（以 下简称《股东大会规则》）、《律师事务所从事证券法律业务管理办法》（以下 简称《证券法律业务管理办法》）、《律师事务所证券法律业务执业规则（试行）》 （以下简称《证券法律业务执业规则》）等相关法律、行政法规、规章、规范性 文件及《浙江亚太药业股份有限公司章程》（以下简称《公司章程》）的规定， 就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序 及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-030 债券代码：128062 债券简称：亚药转债 （一）召开时间：2024 年 4 月 17 日（星期三）15:00-17:00 （二）召开方式：网络远程方式 （三）参与方式：投资者可登陆深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩 说明会。 （四）出席本次业绩说明会的人员：公司总经理岑建维先生，董 事会秘书徐炜先生，财务总监徐景阳先生，独立董事吕海洲先生。 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）已于 2024 年 3 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露了《2023 年年度报 告》，为便于广大投资者进一步了解公司情况，公司定于 2024 年 4 月 17 日（星期三）举办 2023 年度网上业绩说明会，具体安排如下： 一、业绩说明会安排 二、投资者问题征集事项 浙江亚太药业股份有限公司 关于举行 2023 年度网上业绩说明会的公告 董 事 会 ...

证券代码：002370 证券简称：亚太药业 公告编号：2024-029 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 二、转股价格调整情况 2024 年第一季度可转换公司债券转股情况公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 特别提示 股票代码：002370 股票简称：亚太药业 债券代码：128062 债券简称：亚药转债 初始转股价格为 16.30 元/股，最新转股价格为 4.21 元/股 转股日期：2019 年 10 月 9 日至 2025 年 4 月 2 日 根据《深圳证券交易所股票上市规则》《深圳证券交易所可转换 公司债券业务实施细则》等有关规定，浙江亚太药业股份有限公司（以 下简称"亚太药业"或"公司"）现将 2024 年第一季度可转换公司债 券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市概况 经中国证券监督管理委员会《关于核准浙江亚太药业股份有限公 司公开发行可转换公司债券的批复》（证监许可〔2019〕225 号）核准， 公司于 2019 年 4 月 2 日公开发行了 965 万张可转换公 ...

Financial Performance - The company reported a significant increase in revenue for 2023, with total revenue reaching RMB 1.5 billion, representing a year-on-year growth of 15%[1]. - The company's operating revenue for 2023 was CNY 420,643,619.24, representing a 12.64% increase compared to CNY 373,440,356.84 in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY 11,876,965.9, a significant decrease of 91.05% from CNY 132,720,460 in 2022[23]. - The net cash flow from operating activities increased by 21.68% to CNY 14,651,745.8 in 2023, compared to CNY 12,040,719.5 in 2022[23]. - The total assets at the end of 2023 were CNY 1,429,373,407.82, down 6.20% from CNY 1,523,620,707.82 at the end of 2022[23]. - The net assets attributable to shareholders increased by 92.81% to CNY 580,874,409.53 in 2023, compared to CNY 301,220,340 in 2022[23]. - The basic and diluted earnings per share for 2023 were both -0.02, an improvement of 92.00% from -0.25 in 2022[23]. - The company reported a decrease in the weighted average return on net assets to -3.42% in 2023 from -36.12% in 2022[23]. - The company reported a significant reduction in non-recurring gains and losses, with the net profit excluding these losses at CNY 68,944,529.1, down 40.86% from CNY 116,646,722 in 2022[23]. - The company reported a reduced operating loss of ¥63,453,290.39, a decrease of 45.57% compared to the previous year[51]. - The total net loss attributable to shareholders was ¥11,876,965.92, reflecting a 91.05% reduction in losses year-on-year[51]. User Growth and Market Expansion - User data showed an increase in active users, with the total number of active users rising to 2 million, up 20% compared to the previous year[1]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[1]. - The company plans to invest RMB 200 million in upgrading its manufacturing facilities to comply with new regulatory standards[1]. - The company is actively pursuing OEM and CMO/CDMO projects to diversify its revenue streams and enhance its market presence[47]. - The company is expanding its sales network across provinces and enhancing its marketing strategies to improve sales efficiency and market share[47]. - The company plans to enter two new international markets by the end of 2024, aiming to increase its global footprint[130]. Research and Development - Research and development efforts have led to the introduction of three new innovative drugs, with expected market approval by Q3 2024[1]. - The company is investing 100 million RMB in R&D for new technologies in the upcoming year[120]. - The company is focusing on increasing its research and development efforts, particularly in key product areas, to enhance core competitiveness[96]. - The company has initiated several new product development projects, with ongoing clinical trials and regulatory submissions for various drugs[64]. - The company has completed 12 products that have passed consistency evaluation, with 3 products entering national centralized procurement[51]. - The company has obtained drug registration certificates for several new products, including non-fluorinated drugs, indicating progress in product line expansion[64]. - The company is committed to a "combination of imitation and innovation" strategy, focusing on high-end generics and innovative drug development[44]. Financial Management and Investments - The company has not declared any cash dividends for the year, focusing instead on reinvestment for growth initiatives[1]. - The total amount of funds raised from the issuance of convertible bonds was RMB 965 million, with a net amount of RMB 955 million after deducting underwriting fees[83]. - The company has not made any changes to the use of raised funds, and there are no plans for additional fundraising[85]. - The company has established a comprehensive salary management system and evaluation mechanism to attract and retain talent, emphasizing fairness and market alignment[143]. - The company has reported a total revenue of 19,991,770.80 CNY for the year, with interest income of 3,140.37 CNY and overdue penalty interest included[185]. Regulatory and Compliance - Risk factors highlighted include potential regulatory changes and increased competition in the pharmaceutical sector, which the company is actively monitoring[1]. - The company has adjusted its accounting policies due to changes in regulations effective from January 1, 2023, impacting the presentation of financial statements[23]. - The company is actively monitoring industry policy changes to mitigate risks associated with regulatory compliance and procurement policies[99]. - The company emphasizes the importance of drug quality and has established a comprehensive quality control system, adhering to GMP standards to mitigate risks associated with drug quality[101]. - The company is aware of the litigation risks stemming from past regulatory penalties and is taking steps to manage these potential liabilities[104]. Governance and Management - The company underwent a change in its controlling shareholder, now being held by Ningbo Fubon Holding Group Co., Ltd., with a shareholding ratio of 18.02%[21]. - The management team has undergone changes, with a new CEO appointed effective February 7, 2024[118]. - The board of directors has been restructured, with new appointments aimed at strengthening governance[118]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and protection of shareholder rights[109]. - The company has a dedicated financial department and independent bank accounts, ensuring no shared accounts with the controlling shareholder[113]. Legal and Litigation Matters - The company is involved in a legal dispute with Wuhan Rural Commercial Bank, with a total amount involved of 19,999,490 CNY, which has led to the freezing of the company's bank accounts[184]. - The company has initiated legal proceedings against Green Villa Holdings Ltd. for the unpaid performance compensation, with a court hearing scheduled for November 5, 2024[173]. - The company is actively managing its legal risks and has taken steps to appeal unfavorable judgments in order to protect its financial interests[185]. - The company has faced multiple lawsuits related to securities false statements, with compensation amounts ranging from 1.23 million CNY to 15.67 million CNY for different cases[185]. - The company has received a civil judgment requiring the payment of CNY 256.38 million, which reflects the seriousness of the ongoing legal matters[186]. Environmental and Social Responsibility - The company has actively engaged in environmental protection, achieving ISO 14001 certification and implementing measures to reduce carbon emissions and manage waste effectively[164]. - The company has established a comprehensive internal control system to ensure the accuracy and reliability of financial reporting[151]. - The company has established a hazardous waste storage facility to classify and store hazardous waste generated during production, ensuring timely disposal by qualified units[159]. - The company conducts environmental monitoring, with quarterly checks on particulate matter emissions limited to 15 mg/Nm3 as per industry standards[160]. - The company has implemented a self-monitoring scheme for environmental compliance, ensuring adherence to established standards and limits[159].

浙江亚太药业股份有限公司 内部审计制度 浙江亚太药业股份有限公司 内部审计制度 第二条 本制度所称内部审计，是指由公司内部机构或人员，对公司内部控 制和风险管理的有效性、财务信息的真实性和完整性以及经营管理活动的效率和 效果等开展的一种评价活动。 第三条 公司董事会应当对内部控制制度的建立健全和有效实施负责，重要 的内部控制制度应当经董事会审议通过。 公司董事会及其全体成员应当保证内部控制相关信息披露内容的真实、准 确、完整。 第四条 公司董事、高级管理人员、公司各部门及各控股子公司的财务收支 与业务活动均接受内部审计的监督检查。 第二章 内部审计机构和审计人员 第五条 公司在董事会下设立审计委员会，审计委员会统一领导、指导和监 督公司的内部审计工作，并向董事会报告内部审计工作。 第六条 公司在董事会审计委员会下设立内部审计部门，内部审计部门是公 司内部审计机构, 对公司内部控制制度的建立和实施、公司财务信息的真实性 和完整性等情况进行检查监督。内部审计部门对审计委员会负责，向审计委员 会报告工作，在审计委员会的指导和监督下开展工作。 第一章 总 则 第一条 为了进一步规范浙江亚太药业股份有限公司（以下简称" ...